Ravindra Sarode, MD
Blood Banking & Transfusion Medicine · Dallas, TXNPI 1265493688
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Argenx US, Inc. at 35.7% of the total. Reporting peaked in 2023 at $26,632 and has fallen 78.2% since, to $5,816 in 2025.
Across 100 payments — averaging $797.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$28K
- CSL Behring$18K
- Octapharma USA, Inc.$7K
- Sanofi$6K
- Novo Nordisk$5K
- Merck$5K
- plus $10K from 16 others
Across 87 payments — averaging $15,113 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cerus Corporation$1.2M
- Siemens Medical Solutions USA, Inc.$88K
- Octapharma USA, Inc.$65K
What the payments were for
- Consulting fees$41,86552%
- Speaking & faculty fees$22,34728%
- Grants$5,1356%
- Travel & lodging$3,1624%
- Food & beverage$7,2459%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 4 | $28,487 |
| CSL Behring | 4 | $17,847 |
| Octapharma USA, Inc. | 15 | $6,691 |
| Sanofi | 10 | $6,355 |
| Novo Nordisk | 4 | $5,380 |
| Merck | 8 | $5,260 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,500 |
| Cerus Corporation | 7 | $2,358 |
| Abbott | 19 | $1,945 |
| Siemens Medical Solutions USA, Inc. | 7 | $725 |
| Gilead | 3 | $388 |
| AstraZeneca(2 entities) | 3 | $324 |
| Novartis | 3 | $324 |
| Sanofi-aventis U.S. LLC | 3 | $315 |
| Fresenius Kabi USA, LLC | 2 | $228 |
| Baxter Healthcare | 1 | $132 |
| Werfen USA LLC | 1 | $129 |
| ADMA Biomanufacturing LLC | 1 | $126 |
| Therakos LLC | 1 | $126 |
| Diagnostica Stago, Inc | 1 | $85 |
| Roche Diagnostics Corporation | 1 | $28 |
| Cvrx, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$28,487
- Kcentra$17,847
- VYVGART HYTRULO$12,812
- CABLIVI$4,023
- FIBRYGA$3,114
- BALFAXAR$3,074
- INTERCEPT BLOOD SYSTEM FOR PLATELETS$2,180
- Alinity$879
- Automated Blood Coagulation Analyzer CS-5100$460
- Alinity c$339
- Yescarta$292
- Alinity m$292
- REBINYN$245
- I-STAT$171
- No Related Product$132
- ULTOMIRIS$129
- UVADEX$126
- CELLEX$126
- Amicus Separator$125
- ENJAYMO$125
How this compares
Too few blood banking & transfusion medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other blood banking & transfusion medicine in Dallas
- Laurie SutorDallas$90K
- Sean YatesDallas$8K
- James BurnerDallas$778
- Christopher WebbDallas$400
- Mary TownsendAmarillo$34K
- Arthur BraceyHouston$8K
- Hlaing TintHouston$430
- Susan RossmannHouston$418
- Christopher GonzalezTemple$292
- Frances BenoistBedford$166
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.